Welcome by Hans Schambye, Chairman - DANSK BIOTEK & Nils Bang, Partner – Gorrissen Federspiel
AMR surveillance, research and development by Robert Skov, National AMR Coordinator, Division of Infectious Disease Preparedness and Carina Vingsbo Lundsbo, Head of Preclinical Development of Antimicrobials - Statens Serum Institut
The CRISPR approach in life threatening diseases with AMR bacteria by Lene Jessen, VP, Head of In vivo Pharmacology & Toxicology - SNIPR Biome
Leveraging small molecules to tackle resistance by Rasmus Toft-Kehler, CEO - UNION therapeutics A/S
Developing vaccines for antibiotic resistance by Per Fischer, CEO - MinervaX ApS
The REPAIR Impact Fund by Aleks Engel, Partner – Novo Seeds
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.